

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19391 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/48**,  
A61P 31/04, A61K 9/06

NY 11552 (US). **LOOMIS**, Lawrence [US/US]; 11374  
Buckelberry Path, Columbia, MD 21044 (US).

(21) International Application Number: PCT/US00/01237

(74) Agents: **SANDERCOCK**, Colin, G. et al.; Foley & Lard-  
ner, 3000 K. Street, NW, Washington, DC 20007-5109  
(US).

(22) International Filing Date: 20 January 2000 (20.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/395,637 14 September 1999 (14.09.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/395,637 (CIP)  
Filed on 14 September 1999 (14.09.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **NEW  
HORIZONS DIAGNOSTICS, INC.** [US/US]; 9110 Red  
Branch Road, Columbia, MD 21045-2014 (US).

Published:  
— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FISCHETTI**,  
Vincent [US/US]; 448 Joan Court, West Hempstead.

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **TOPICAL TREATMENT OF STREPTOCOCCAL INFECTIONS**

(57) Abstract: The present invention discloses a method and composition for the topical treatment of streptococcal infections by the use of a lysin enzyme blended with a carrier suitable for topical application to dermal tissues. The method for the treatment of dermatological streptococcal infections comprises administering a composition comprising effective amount of a therapeutic agent, with the therapeutic agent comprising a lysin enzyme produced by group C streptococcal bacteria infected with a C1 bacteriophage. The therapeutic agent can be in a pharmaceutically acceptable carrier.

WO 01/19391 A1

**THIS PAGE BLANK (USPTO)**

What is claimed is:

- 1) A method for the treatment of dermatological streptococcal infections comprising:  
administering to an infected area of the body a composition comprising effective amount of a therapeutic agent, said therapeutic agent comprising a lysin enzyme produced by group C streptococcal bacteria infected with a C1 bacteriophage.
- 2) The method according to claim 1, further comprising delivering said therapeutic agent in a pharmaceutically acceptable carrier.
- 3) The method according to claim 2, wherein said carrier is selected from the group consisting of an aqueous liquid, an alcohol base, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, hydrophilic gelling agents, cross-linked acrylic acid polymers (carbomers), cellulose polymers, hydroxy ethyl cellulose, cellulose gum, MVE/MA decadiene crosspolymers, PVM/MA copolymers, and any combinations thereof.
- 4) The method according to claim 1, wherein the form in which the composition is delivered is selected from the group consisting of a spray, a smear, a time release patch, a liquid absorbed wipe, and any combinations thereof.
- 5) The method according to claim 1, wherein the lysin enzyme is in an environment having a pH which allows for activity of said lysin enzyme.
- 6) The method according to claim 5, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.

7) The method according to claim 6, wherein said buffer maintains the pH of the composition at the range of between about 5.5 and about 7.5.

8) The method according to claim 6, wherein said buffer comprises a reducing agent.

9) The method according to claim 8, wherein said reducing agent is dithiothreitol.

10) The method according to claim 6, wherein said buffer comprises a metal chelating reagent.

11) The method according to claim 10, wherein said metal chelating reagent is ethylenediaminetetraacetic disodium salt.

12) The method according to claim 6, wherein said buffer is a citrate-phosphate buffer.

13) The method according to claim 6, further comprising a bactericidal or bacteriostatic agent as a preservative.

14) The method according to claim 1, wherein the therapeutic agent further comprises a mild surfactant in an amount effective to potentiate the therapeutic effect of the lysin enzyme.

15) The method according to claim 1, wherein the therapeutic agent further comprises at least one complementary agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of penicillin, synthetic penicillins bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil,

cefamandole nafate, cefazolin, cefixime, cefmetazole, cefoniod, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, ceftriaxone moxalactam, cefuroxime, cephalixin, cephalosporin C, cephalosporin C sodium salt, cephalothin, cephalothin sodium salt, cephapirin, cephradine, cefuroximeaxetil, dihydratecephalothin, moxalactam, loracarbef, mafate and chelating agents in an amount effective to synergistically enhance the therapeutic effect of the lysin enzyme.

16) The method according to claim 1, wherein the therapeutic agent further comprises lysostaphin for the treatment of any *Staphylococcus aureus* bacteria.

17) The method according to claim 1, wherein the therapeutic agent further comprises mutanolysin.

18) The method according to claim 1, wherein the therapeutic agent further comprises lysozyme.

19) The method according to claim 1, wherein said lysin enzyme is present in an amount ranging from about 100 to about 500,000 units per milliliter.

20). The method according to claim 19, wherein said lysin enzyme is present in an amount ranging from about 1,000 units to about 100,000 units per milliliter.

21) The method according to claim 20, wherein said lysin enzyme is present in an amount ranging from about 10,000 units to about 100,000 units per milliliter.

22) A composition for the treatment of dermatological streptococcal infections comprising:

an effective amount of a therapeutic agent, said therapeutic agent comprising a lysin enzyme produced by group C streptococcal bacteria infected with a C1 bacteriophage, and a pharmaceutically acceptable carrier for topical application of the lysin enzyme.

23) The composition according to claim 22, wherein said carrier is selected from the group consisting of an aqueous liquid, an alcohol base, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, hydrophilic gelling agents, cross-linked acrylic acid polymers (carbomers), cellulose polymers, hydroxy ethyl cellulose, cellulose gum, MVE/MA decadiene crosspolymers, PVM/MA copolymers, and any combinations thereof.

24) The composition according to claim 22, wherein said composition is in the form selected from the group consisting of a spray, a smear, a time release patch, a liquid absorbed wipe, and any combinations thereof.

25) The composition according to claim 22, wherein the lysin enzyme is in an environment having a pH which allows for activity of said lysin enzyme.

26) The composition according to claim 20, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.

27) The composition according to claim 26, wherein said buffer maintains the pH of the composition at the range of between about 5.5 and about 7.5.

28) The composition according to claim 26, wherein said buffer comprises a reducing agent.

29) The composition according to claim 28, wherein said reducing agent is dithiothreitol.

30) The composition according to claim 26, wherein said buffer comprises a metal chelating reagent.

31) The composition according to claim 30, wherein said metal chelating reagent is ethylenediaminetetraacetic disodium salt.

32) The composition according to claim 26, wherein said buffer is a citrate-phosphate buffer.

33) The composition according to claim 22, further comprising a bactericidal or bacteriostatic agent as a preservative.

34) The composition according to claim 22, further comprising a surfactant in an amount effective to potentiate the therapeutic effect of the therapeutic agent.

35) The composition according to claim 22, wherein the therapeutic agent further comprises at least one complementary agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of penicillin, synthetic penicillins bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefmetazole, cefoniod, cefoperazone,

ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, cefriaxone moxalactam, cefuroxime, cephalixin, cephalosporin C, cephalosporin C sodium salt, cephalothin, cephalothin sodium salt, cephapirin, cephradine, cefuroximeaxetil, dihydratecephalothin, moxalactam, loracarbef, mafate chelating agents, and combinations thereof in an amount effective to synergistically enhance the therapeutic effect of the lysin enzyme.

36) The composition according to claim 22, wherein the therapeutic agent further comprises lysostaphin for the treatment of any *Staphylococcus aureus* bacteria.

37) The composition according to claim 22, wherein the therapeutic agent further comprises  
mutanolysin.

38) The composition according to claim 22, wherein the therapeutic agent further comprises  
lysozyme.

39) The composition according to claim 22, wherein said lysin enzyme is present in an amount ranging from about 100 to about 500,000 units per milliliter.

40). The composition according to claim 22, wherein said lysin enzyme is present in an amount ranging from about 1,000 units to about 100,000 units per milliliter.

41) The composition according to claim 22, wherein said lysin enzyme is present in an amount ranging from about 10,000 units to about 100,000 units per milliliter.



- 42) The composition according to claim 22, further comprising at least one emulsifier.
- 43) The composition according to claim 22, further comprising at least one antioxidant.
- 44) The composition according to claim 22, further comprising at least one sunscreen.
- 45) The composition according to claim 22, further comprising at least one preservative.
- 46) The composition according to claim 22, further comprising at least one anti-inflammatory agent.
- 47) The composition according to claim 22, further comprising at least one local anesthetic.
- 48) The composition according to claim 22, further comprising at least corticosteroid.
- 49) The composition according to claim 22, further comprising at least one destructive therapy agent.

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

Inter. Application No  
PCT/US 00/01237

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7    A61K38/48    A61P31/04    A61K9/06		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7    A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, EPO-Internal, PAJ, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X, L	US 5 997 862 A (FISCHETTI ET AL.) 7 December 1999 (1999-12-07) the priority claim of the present application might not be partially justified. the whole document	22-32, 43, 45
Y	US 5 604 109 A (FISCHETTI ET AL.) 18 February 1997 (1997-02-18) cited in the application claim 19	1-7, 19, 39
Y	FR 2 357 246 A (MARTINEZ) 3 February 1978 (1978-02-03) the whole document	1-7, 19, 39
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>*8* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
27 June 2000	14/07/2000	
Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Benz, K	

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/01237

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI  Week 9838  Derwent Publications Ltd., London, GB;  AN 1988-444917  XP002141110  &amp; RU 2 103 991 C (IMMUNOPREPARAT RES PRODN  ASSOC), 10 February 1998 (1998-02-10)  abstract</p> <p style="text-align: center;">---</p>	<p>22,23,  25,26</p>
X	<p>DATABASE WPI  Week 9715  Derwent Publications Ltd., London, GB;  AN 1997-163380  XP002141111  &amp; RU 2 064 299 C (AS USSR MICROORGANISMS  BIOCHEM PHYSIOLOG ET AL.)  abstract</p> <p style="text-align: center;">---</p>	<p>22,23,  25,26</p>
A	<p>US 4 062 941 A (DAVIES)  13 December 1977 (1977-12-13)  the whole document</p> <p style="text-align: center;">-----</p>	

THIS PAGE BLANK (USPTO)

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5997862	A	07-12-1999	US 6017528 A	25-01-2000
			US 5985271 A	16-11-1999
			US 6056954 A	02-05-2000
-----				
US 5604109	A	18-02-1997	AU 8108587 A	06-05-1988
			CA 1301645 A	26-05-1992
			EP 0285649 A	12-10-1988
			JP 1501338 T	11-05-1989
			JP 2837846 B	16-12-1998
			WO 8802781 A	21-04-1988
-----				
FR 2357246	A	03-02-1978	NONE	
-----				
RU 2103991	C		NONE	
-----				
RU 2064299	C	27-07-1996	NONE	
-----				
US 4062941	A	13-12-1977	GB 1542848 A	28-03-1979
-----				

**THIS PAGE BLANK (USPTO)**